Pharma BD Deal Intelligence
A niacin franchise that grew on marketing momentum and a false clinical thesis: Abbott's $3.7B/$78-a-share buy of Kos rode Niaspan to ~$1.1B in US sales before the AIM-HIGH trial (2011) found no cardiovascular benefit and a stroke signal, triggering generic erosion and an outright FDA withdrawal of the niacin-combo products in 2016.
Niaspan rode a marketing-driven prescription boom to ~$1.1B in US sales, then the clinical rationale collapsed (AIM-HIGH, 2011) and the FDA ultimately pulled the niacin-combo products from the market in 2016 — a franchise built on a thesis that didn't survive its own trial data.
Full analysis, sources & comparables →Abbott expects the transaction to be $0.02 to $0.03 dilutive to ongoing earnings per share in 2007, neutral to accretive in 2008 and building to significant…
Abbott's $78-per-share cash offer represented a premium of nearly 56 percent over Kos's Friday close of $50.09; Kos's main products Niaspan and Advicor are…
Kos board recommended Abbott's $78/share tender offer; financial advisors confirmed fairness based on Niaspan franchise economics, Simcor pipeline value and…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Cardiovascular/lipid management; Niaspan, Advicor; $78/share
Niaspan rode a marketing-driven prescription boom to ~$1.1B in US sales, then the clinical rationale collapsed (AIM-HIGH, 2011) and the FDA ultimately pulled the niacin-combo products from the market in 2016 — a franchise built on a thesis that didn't survive its own trial data.
Assessment window: 15yr post-close.
$20.0B Global lipid management market 2006
Dyslipidemia covers abnormal blood lipid levels — high LDL ('bad') cholesterol, high triglycerides, or low HDL ('good') cholesterol — the principal modifiable risk factor for atherosclerotic cardiovascular disease. While statins dominate LDL reduction, HDL-raising and triglyceride-lowering remain unmet needs.
In 2006 the $20B lipid market was dominated by LDL-lowering statins — Pfizer's Lipitor (atorvastatin, ~$13B), Merck's Zocor (simvastatin, going generic) and AstraZeneca's Crestor (rosuvastatin) — plus Merck/Schering-Plough's Vytorin (ezetimibe/simvastatin) and Zetia. Kos differentiated on HDL: Niaspan (extended-release niacin, launched 1997) and Advicor (niacin/lovastatin), the only major HDL-raising franchise on the US market. Abbott's $78/share, $3.7B cash bid (56% premium) added Kos to its existing Tricor (fenofibrate) franchise, creating a broader cardiometabolic platform and giving Abbott a vehicle to compete beside the statin majors. The pipeline included Simcor (niacin/simvastatin, FDA submission H1 2007), a low-flush Niaspan reformulation, late-stage asthma combo Flutiform, and an inhaled insulin candidate. Analysts viewed the premium as steep but consistent with 2006-era pipeline-fill M&A: 'big premiums are becoming the norm for acquisitions in the drug sector'. The deal cemented Abbott's lipid franchise ahead of the 2006-2007 statin patent cliff and broadened beyond cardiovascular into respiratory and diabetes optionality.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Abbott Laboratories / Kos Pharmaceuticals Inc. (this deal) | 2006 | $3.7B | 33 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Abbott Laboratories / Knoll Pharmaceuticals (BASF Pharma) | 2000 | $6.9B | 95 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
| Abbott Laboratories / St. Jude Medical | 2016 | $30.5B | 82 |
| Abbott Laboratories / TheraSense Inc. | 2004 | $1.2B | 81 |
| Abbott Laboratories / Vysis Inc. | 2001 | $355M | 79 |
← Browse all deals · How we score deals
More: 2006 deals · Abbott Laboratories deals